What Happened: Susi's recent Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday unveiled the sale of 5,000 shares of iRadimed. The total transaction value is $488,316.

Between exiting the Smiths remediation process, leveraging new product introductions (and overhead leverage), and ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

Baxter International BAX is currently in transition following the divestiture of Kidney Care, balancing near-term execution ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Roger E Susi, CEO at iRadimed (NASDAQ: IRMD ), disclosed an insider sell on December 22, according to a recent SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma.

LUNSUMIO (mosunetuzumab-axgb) or LUNSUMIO VELO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who ...